Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Imiquimod‐induced vitiligo after treatment of nodular basal cell carcinoma
Smitha Gowda, Donald K. Tillman, James E. Fitzpatrick, et al.
Journal of Cutaneous Pathology (2009) Vol. 36, Iss. 8, pp. 878-881
Closed Access | Times Cited: 21

Showing 21 citing articles:

Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil
V. Florin, E. Desmedt, S. Vercambre‐Darras, et al.
Investigational New Drugs (2011) Vol. 30, Iss. 4, pp. 1641-1645
Closed Access | Times Cited: 56
Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management
Xiaoyan Zhang, Yao Xie, Lin Wang
Dermatology and Therapy (2023) Vol. 13, Iss. 9, pp. 1909-1934
Open Access | Times Cited: 12
Epidermal Permeability Barrier Recovery Is Delayed in Vitiligo-Involved Sites
J. Liu, Wenyan Man, Chengzhi Lv, et al.
Skin Pharmacology and Physiology (2010) Vol. 23, Iss. 4, pp. 193-200
Open Access | Times Cited: 37
Imiquimod induces apoptosis of human melanocytes
Chul‐Ho Kim, Joo Hee Ahn, Sung Un Kang, et al.
Archives of Dermatological Research (2009) Vol. 302, Iss. 4, pp. 301-306
Closed Access | Times Cited: 36
Update on childhood vitiligo
Nanette B. Silverberg
Current Opinion in Pediatrics (2010) Vol. 22, Iss. 4, pp. 445-452
Closed Access | Times Cited: 33
Lupus Erythematosus–Like Reaction in Imiquimod-Treated Skin: A Report of 2 Cases
May P. Chan, Mary Jane Zimarowski
American Journal of Dermatopathology (2011) Vol. 33, Iss. 5, pp. 523-527
Closed Access | Times Cited: 29
Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall*
Keira Barr, Thomas Konia, Maxwell A. Fung
Journal of Cutaneous Pathology (2010), pp. no-no
Closed Access | Times Cited: 20
Dermatoscopy-guided therapy of pigmented basal cell carcinoma with imiquimod
Husein Husein‐ElAhmed, María Antonia Fernández‐Pugnaire
Anais Brasileiros de Dermatologia (2016) Vol. 91, Iss. 6, pp. 764-769
Open Access | Times Cited: 12
Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
Vijaypal Arya, Manu Bansal, Lauren Girard, et al.
Case Reports in Dermatology (2010) Vol. 2, Iss. 2, pp. 156-164
Open Access | Times Cited: 14
Vulvar vitiligo-like depigmentation and multiple halos of hypomelanosis at the trunk following treatment with imiquimod 5% cream for vulvar condylomata: casual or related events?
Maíra Chiarelli Serra, Claudia Menicanti, Elisabetta Pennacchioli, et al.
Anais Brasileiros de Dermatologia (2014) Vol. 89, Iss. 5, pp. 806-807
Open Access | Times Cited: 9
Imiquimod-Induced Depigmentation: Report of Two Cases and Review of the Literature
Christopher T. Burnett, David J. Kouba
Dermatologic Surgery (2012) Vol. 38, Iss. 11, pp. 1872-1875
Closed Access | Times Cited: 8
Imiquimod induced vitiligo‐like lesions—A consequence of modified melanocyte function
Haiyan Yu, Jian-Ping Cen, Xiaoxia Lin, et al.
Immunity Inflammation and Disease (2021) Vol. 10, Iss. 1, pp. 70-77
Open Access | Times Cited: 7
Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies
Christopher J. Fay, Samantha Jakuboski, Beth N. McLellan, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 765-785
Closed Access | Times Cited: 2
Cutaneous Side Effects of Chemotherapy and Radiotherapy
Louise Fearfield, J. Natkunarajah
(2016), pp. 1-15
Closed Access | Times Cited: 4
Cutaneous Side Effects of Chemotherapy and Radiotherapy
Louise Fearfield, Charlotte Edwards
(2024), pp. 1-17
Closed Access
Vitiligo: A new side effect of everolimus therapy for metastatic renal cell carcinoma
Sara Cacciapuoti, Anna Masarà, Maria Mariano, et al.
Australasian Medical Journal (2017) Vol. 10, Iss. 10
Open Access | Times Cited: 1
Pharmacotherapy of Basal Cell Carcinoma, Anogenital Warts, and Actinic Keratoses: Focus on Topical Imiquimod
Caroline Caperton, Martha H. Viera, Sadegh Amini, et al.
Clinical Medicine Reviews in Oncology (2011) Vol. 3, pp. 13-27
Closed Access
Giant basal cell carcinoma. Improvement and vitiligo-like hypopigmentation after intermittent treatment with 5% imiquimod.
Francisco Urbina
PubMed (2012) Vol. 20, Iss. 4, pp. 275-8
Closed Access
Hipopigmentación tipo vitíligo relacionada con tratamiento con imiquimod
Benigno Monteagudo, M. Cabanillas, Víctor Manuel López-Mouriño, et al.
Piel (2009) Vol. 24, Iss. 9, pp. 513-513
Closed Access
Current awareness: Pharmacoepidemiology and drug safety

Pharmacoepidemiology and Drug Safety (2009) Vol. 19, Iss. 1
Closed Access
Réactivation d’un lupus érythémateux subaigu après application d’imiquimod
M. Terrasa, K. Khelef, C. Bédane, et al.
Annales de Dermatologie et de Vénéréologie - FMC (2021) Vol. 2, Iss. 3, pp. 213-217
Open Access
Page 1

Scroll to top